Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Multiple other molecules with different routes of administration (such as oral GLP-1 RAs) and/or different mechanisms of action (such as injectable combinations of entero-pancreatic hormones) have shown promising data in early phase clinical trials and are currently undergoing phase 3 trials as treatments for T2D, obesity and other metabolic complications (e.c MASH, HFpEF) with some of them having the potential to induce even more WL and/or metabolic benefits compared to tirzepatide
Investment varies based on your specific protocol
Always remember that bacteriostatic water is only suitable for injection purposes and cannot be employed for irrigation, wound care, or in any way that involves direct exposure to the tissues
FDA Assessment FDA found insufficient evidence supporting intravenous emideltide for opioid withdrawal and no evidence supporting the nominated subcutaneous route
Zepbound (tirzepatide) On February 23, 2026, Novo Nordisk shared results from a study that directly compared CagriSema to Zepbound
US$ 28.41
US$ 27.56
US$ 26.94
US$ 23.78
US$ 22.72
US$ 20.34